Card-20(22)-enolide,3-[(6-deoxy-a-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-,(1b,3b,5b,11a)- cas no:630-60-4

NameCard-20(22)-enolide,3-[(6-deoxy-a-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-,(1b,3b,5b,11a)-
CAS630-60-4
SynonymsOuabain(8CI); Acocantherin; Astrobain; Gratibain; Gratus strophanthin; Kombetin; NSC25485; Ouabaine; Purostrophan; Rectobaina; Solufantina; Strodival; Strophalen;Strophoperm; Strophosan; Uabaina; Uabanin; g-Strophanthin; g-Strophicor
EINECS(EC#)211-139-3
Molecular FormulaC29H44 O12
Molecular Weight584.73

AppearanceOdorless, white crystals or crystalline powder as an octahydrate
refractive index-32 ° (C=1, H2O)
storage tempDesiccate at -20°C

Hazard T
Risk 23/25-33
Safety

Poison by ingestion, intramuscular, intraperitoneal, intravenous, subcutaneous, and parenteral routes. Moderately toxic by intraduodenal route. A cardiac stimulant. Mutation data reported. When heated to decomposition it emits acrid smoke and irritating fumes.
Safety Information of Ouabain (630-60-4):
Hazard Codes: T
Risk Statements: 23/25-33 
23:  Toxic by inhalation
25:  Toxic if swallowed
33:  Danger of cumulative effects
Safety Statements: 45
45:  May cause cancer
 Ouabain (630-60-4) is classified as extremely toxic. Probable oral lethal dose in humans is less than 5 mg/kg or a taste (less than 7 drops) for 70 kg (150-lb.) person. Exposure may result in respiratory and cardiac failure, and/or hyperalkemia. Patients with frequent premature ventricular heart beats or who have received any preparation of digitalis during preceding three weeks are prone to toxicity.When heated to decomposition, Ouabain (630-60-4) emits acrid smoke and fumes. Hydrolysis yields one mole ouabagenin and one mole rhamnose. Stable in air, but affected by light ( Ouabain octahydrate).

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
cat	LD50	intraperitoneal	100ug/kg (0.1mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 155, Pg. 165, 1965.
cat	LD50	intravenous	100ug/kg (0.1mg/kg)		Proceedings of the Society for Experimental Biology and Medicine. Vol. 35, Pg. 316, 1936.
cat	LDLo	intraduodenal	820ug/kg (0.82mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 557, 1958.
cat	LDLo	oral	5mg/kg (5mg/kg)		Farmacognosia. Vol. 13, Pg. 375, 1953.
cat	LDLo	subcutaneous	150ug/kg (0.15mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
cat	LDLo	unreported	90ug/kg (0.09mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 148, Pg. 471, 1964.
dog	LDLo	intravenous	54ug/kg (0.054mg/kg)	CARDIAC: CHANGE IN RATE	Journal of Pharmacology and Experimental Therapeutics. Vol. 179, Pg. 447, 1971.
dog	LDLo	oral	1500ug/kg (1.5mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
dog	LDLo	subcutaneous	100ug/kg (0.1mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
frog	LD50	intravenous	250ug/kg (0.25mg/kg)		Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 61, Pg. 231, 1965.
frog	LD50	parenteral	370ug/kg (0.37mg/kg)		Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 53, Pg. 995, 1957.
frog	LDLo	subcutaneous	400ug/kg (0.4mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
guinea pig	LD50	intraperitoneal	210ug/kg (0.21mg/kg)		Acta Biologica et Medica Germanica. Vol. 12, Pg. 434, 1964.
guinea pig	LD50	intravenous	228ug/kg (0.228mg/kg)		Acta Biologica et Medica Germanica. Vol. 12, Pg. 434, 1964.
guinea pig	LD50	oral	8280ug/kg (8.28mg/kg)		United States Patent Document. Vol. #4230702,
guinea pig	LD95	intraduodenal	3340ug/kg (3.34mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 557, 1958.
guinea pig	LDLo	intraarterial	40ug/kg (0.04mg/kg)		Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 131, Pg. 171, 1928.
guinea pig	LDLo	intramuscular	220ug/kg (0.22mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 52, Pg. 1, 1934.
guinea pig	LDLo	subcutaneous	100ug/kg (0.1mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
monkey	LDLo	intravenous	102ug/kg (0.102mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 13, Pg. 412, 1963.
mouse	LD50	intracrebral	69ug/kg (0.069mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Pharmacological Research Communications. Vol. 6, Pg. 417, 1974.
mouse	LD50	intraperitoneal	11mg/kg (11mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 155, Pg. 165, 1965.
mouse	LD50	intravenous	2200ug/kg (2.2mg/kg)		Proceedings of the Society for Experimental Biology and Medicine. Vol. 118, Pg. 756, 1965.
mouse	LD50	oral	5mg/kg (5mg/kg)		Japanese Journal of Toxicology. Vol. 4, Pg. 105, 1991.
mouse	LD50	subcutaneous	5mg/kg (5mg/kg)		Japanese Journal of Toxicology. Vol. 4, Pg. 105, 1991.
pigeon	LDLo	intramuscular	330ug/kg (0.33mg/kg)		Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 149, Pg. 306, 1909.
pigeon	LDLo	intravenous	183ug/kg (0.183mg/kg)	CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) GASTROINTESTINAL: NAUSEA OR VOMITING CARDIAC: CHANGE IN RATE	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 126, Pg. 412,1960.
pigeon	LDLo	oral	14mg/kg (14mg/kg)		Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 149, Pg. 306, 1909.
rabbit	LD50	intravenous	252ug/kg (0.252mg/kg)		Pharmacological Research Communications. Vol. 13, Pg. 571, 1981.
rabbit	LDLo	intramuscular	1mg/kg (1mg/kg)		Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 149, Pg. 306, 1909.
rabbit	LDLo	oral	7mg/kg (7mg/kg)		Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 149, Pg. 306, 1909.
rabbit	LDLo	subcutaneous	100ug/kg (0.1mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
rat	LD50	intravenous	14mg/kg (14mg/kg)		Toxicology and Applied Pharmacology. Vol. 20, Pg. 44, 1971.
rat	LD50	unreported	125mg/kg (125mg/kg)		Toxicology and Applied Pharmacology. Vol. 22, Pg. 336, 1972.
rat	LDLo	subcutaneous	50mg/kg (50mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.